Compare Marathon Petroleum Corp (MPC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs TransMedics Group Inc — how do they compare? Marathon Petroleum Corp trades at $460 (market cap $130.12B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: Marathon Petroleum Corp is far larger — about 47.5× TransMedics Group Inc's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and TransMedics Group Inc for 24 Days on average.
| MPC | TMDX | |
|---|---|---|
Market Cap | $130.12B | $2.74B |
Volume | 2,749,647 | 949,331 |
Sector | Energy | Health |
52-Week High | $463.34 | $150.42 |
52-Week Low | $162.63 | $61.99 |
Typical Hold Time | 54 Days | 24 Days |
Enterprise Value | $156.64B | $3.13B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $442.26, up 2.29% today, reflecting strong momentum amid bullish technical signals and recent earnings beats. The stock shows robust profitability with a 47.9% ROE and trades at a P/E of 16.07, below the sector average. Recent news highlights refining margin strength and positive analyst sentiment, though risks include potential diesel export restrictions and volatile energy markets.
Outlook remains positive with 75.8% of analysts rating it a buy and a consensus price target of $420.30. Key opportunities include elevated refining margins and solid cash flow, while risks involve regulatory uncertainty and cyclical demand pressures. The stock's valuation and growth prospects support a constructive view for investors seeking energy exposure.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
